{
  "abstract": "Background: Chimeric antigen receptor (CAR) T-cell therapy can produce durable remission in refractory hematologic malignancies, but the expanding survivor population has focused attention on second primary malignancies (SPMs). Interpretation is difficult because recipients already carry substantial age-, disease-, and treatment-related cancer risk; follow-up is often short; outcome definitions vary; and competing mortality is high.\n\nMain body: This critical review integrates epidemiologic, genomic, mechanistic, and regulatory evidence into a causal framework. Available evidence is consistent with a multistep clonal-evolution model: pre-existing clonal hematopoiesis and cumulative genotoxic injury establish the substrate; lymphodepletion, marrow inflammation, regenerative stress, and altered immune surveillance modify clonal fitness; and additional events permit transformation. Therapy-related myeloid neoplasms are the most actionable subgroup. By contrast, T-cell malignancies derived from CAR-modified cells are exceptionally rare and require direct lineage and vector analysis because detection of a CAR sequence alone does not prove insertional oncogenesis. We propose a graded attribution ladder and a risk-adapted surveillance pathway centered on serial blood counts, prompt evaluation of unexplained cytopenias or lymphoid abnormalities, age-appropriate cancer screening, and mechanism-specific molecular testing.\n\nConclusion: Temporal association should not be equated with causation. Prospective denominator-based cohorts, matched comparators, paired biospecimens, integration-site mapping, and single-cell lineage reconstruction are needed to distinguish background risk, treatment-associated clonal selection, and true product-related oncogenesis.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hematology, Dongyang People’s Hospital (Affiliated Dongyang Hospital of Wenzhou Medical University)"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Sihui Huang"
    },
    {
      "affs": [
        0
      ],
      "name": "Yang Jin"
    },
    {
      "affs": [
        0
      ],
      "name": "Panruo Jiang"
    },
    {
      "affs": [
        0
      ],
      "name": "Gongqiang Wu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3568y05eqy0fa.bib",
  "cited_by": 0,
  "doi": "10.3389/fimmu.2026.2014066",
  "fulltext_url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.2014066/full",
  "id": "3568y05eqy0fa",
  "issns": [
    "1664-3224"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.2014066/full",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC581-607"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-16",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/3568y05eqy0fa.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:24:40Z",
      "native_id": "10.3389/fimmu.2026.2014066",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.2014066/full"
    },
    {
      "first_seen": "2026-11-16T15:21:14Z",
      "native_id": "0232f47753e54715816cfd1b252da76b",
      "source": "doaj",
      "url": "https://doi.org/10.3389/fimmu.2026.2014066"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "issn:1664-3224",
      "subfield": "immunology"
    },
    {
      "field": "medicine",
      "origin": "lcc:RC581-607",
      "subfield": "general"
    }
  ],
  "title": "Second primary malignancies after CAR T-cell therapy: causal attribution, clonal evolution, and risk-adapted surveillance",
  "title_text": "Second primary malignancies after CAR T-cell therapy: causal attribution, clonal evolution, and risk-adapted surveillance",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T15:21:14Z",
  "url": "https://research.draconitic.com/paper/3568y05eqy0fa",
  "venue": "Frontiers in Immunology",
  "versions": []
}